Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs

The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2004-05, Vol.93 (5), p.1241-1252
Hauptverfasser: Codrons, Valérie, Vanderbist, Francis, Ucakar, Bernard, Préat, Véronique, Vanbever, Rita
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1252
container_issue 5
container_start_page 1241
container_title Journal of pharmaceutical sciences
container_volume 93
creator Codrons, Valérie
Vanderbist, Francis
Ucakar, Bernard
Préat, Véronique
Vanbever, Rita
description The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004
doi_str_mv 10.1002/jps.20053
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71815083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916315040</els_id><sourcerecordid>71815083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</originalsourceid><addsrcrecordid>eNp1kMtu1TAQhi0EoofCghdA3oDoIq3txE68rCp6oVVBKqhLy7EnHJckDnZSODveoW_Ik-A0h8sC5MVYmm_-0XwIPadknxLCDm6GuM8I4fkDtKKckUwQWj5Eq9RjWc4LuYOexHhDCBGE88doh3IiypKQFRrPukGbEfsGNz50U6tH53use4s7GNfexrk1TG3nex022ELrbiF9ZqiOPgz3_MzooMf1Jnhn8TpF-R7wa_rj-11e7OEm-A6nPm6n_lN8ih41uo3wbFt30cfjNx-OTrOLdydnR4cXmSmkzDMupWVGNkaLmlOqaWVqW3FRFrWsWWOhsLpk6XFeFdRClTeCSamhppILRvJd9GrJHYL_MkEcVeeigbbVPfgpqpJWyUSVJ3BvAU3wMQZo1BBcl-5VlKhZsUqK1b3ixL7Yhk51B_YPuXWagJdbQEej2ybo3rj4FycEJ2wOOli4r66Fzf83qrfvr36tzpYJF0f49ntCh89KlHnJ1fXliUrx9JifX6nrxOcLD0nyrYOgonHQG7AugBmV9e4fB_4ECO20bg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71815083</pqid></control><display><type>article</type><title>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</title><source>MEDLINE</source><source>Wiley Online Library Journals【Remote access available】</source><source>Alma/SFX Local Collection</source><creator>Codrons, Valérie ; Vanderbist, Francis ; Ucakar, Bernard ; Préat, Véronique ; Vanbever, Rita</creator><creatorcontrib>Codrons, Valérie ; Vanderbist, Francis ; Ucakar, Bernard ; Préat, Véronique ; Vanbever, Rita</creatorcontrib><description>The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.20053</identifier><identifier>PMID: 15067700</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Hoboken: Elsevier Inc</publisher><subject>absorption ; Absorption - drug effects ; Absorption - physiology ; Administration, Inhalation ; Animals ; Biological and medical sciences ; Chemistry, Pharmaceutical ; dipalmitoylphosphatidylcholine ; Drug Delivery Systems - methods ; General pharmacology ; human parathyroid hormone ; Humans ; inhalation dry powder ; Lung - drug effects ; Lung - metabolism ; Male ; Medical sciences ; Parathyroid Hormone - administration &amp; dosage ; Parathyroid Hormone - pharmacokinetics ; Peptide Fragments - administration &amp; dosage ; Peptide Fragments - pharmacokinetics ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; pulmonary deposition ; pulmonary drug delivery ; Rats ; Rats, Wistar</subject><ispartof>Journal of pharmaceutical sciences, 2004-05, Vol.93 (5), p.1241-1252</ispartof><rights>2004 Wiley-Liss, Inc.</rights><rights>Copyright © 2004 Wiley‐Liss, Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241-1252, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</citedby><cites>FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.20053$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.20053$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15665023$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15067700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Codrons, Valérie</creatorcontrib><creatorcontrib>Vanderbist, Francis</creatorcontrib><creatorcontrib>Ucakar, Bernard</creatorcontrib><creatorcontrib>Préat, Véronique</creatorcontrib><creatorcontrib>Vanbever, Rita</creatorcontrib><title>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004</description><subject>absorption</subject><subject>Absorption - drug effects</subject><subject>Absorption - physiology</subject><subject>Administration, Inhalation</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>dipalmitoylphosphatidylcholine</subject><subject>Drug Delivery Systems - methods</subject><subject>General pharmacology</subject><subject>human parathyroid hormone</subject><subject>Humans</subject><subject>inhalation dry powder</subject><subject>Lung - drug effects</subject><subject>Lung - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Parathyroid Hormone - administration &amp; dosage</subject><subject>Parathyroid Hormone - pharmacokinetics</subject><subject>Peptide Fragments - administration &amp; dosage</subject><subject>Peptide Fragments - pharmacokinetics</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>pulmonary deposition</subject><subject>pulmonary drug delivery</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtu1TAQhi0EoofCghdA3oDoIq3txE68rCp6oVVBKqhLy7EnHJckDnZSODveoW_Ik-A0h8sC5MVYmm_-0XwIPadknxLCDm6GuM8I4fkDtKKckUwQWj5Eq9RjWc4LuYOexHhDCBGE88doh3IiypKQFRrPukGbEfsGNz50U6tH53use4s7GNfexrk1TG3nex022ELrbiF9ZqiOPgz3_MzooMf1Jnhn8TpF-R7wa_rj-11e7OEm-A6nPm6n_lN8ih41uo3wbFt30cfjNx-OTrOLdydnR4cXmSmkzDMupWVGNkaLmlOqaWVqW3FRFrWsWWOhsLpk6XFeFdRClTeCSamhppILRvJd9GrJHYL_MkEcVeeigbbVPfgpqpJWyUSVJ3BvAU3wMQZo1BBcl-5VlKhZsUqK1b3ixL7Yhk51B_YPuXWagJdbQEej2ybo3rj4FycEJ2wOOli4r66Fzf83qrfvr36tzpYJF0f49ntCh89KlHnJ1fXliUrx9JifX6nrxOcLD0nyrYOgonHQG7AugBmV9e4fB_4ECO20bg</recordid><startdate>200405</startdate><enddate>200405</enddate><creator>Codrons, Valérie</creator><creator>Vanderbist, Francis</creator><creator>Ucakar, Bernard</creator><creator>Préat, Véronique</creator><creator>Vanbever, Rita</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200405</creationdate><title>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</title><author>Codrons, Valérie ; Vanderbist, Francis ; Ucakar, Bernard ; Préat, Véronique ; Vanbever, Rita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>absorption</topic><topic>Absorption - drug effects</topic><topic>Absorption - physiology</topic><topic>Administration, Inhalation</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>dipalmitoylphosphatidylcholine</topic><topic>Drug Delivery Systems - methods</topic><topic>General pharmacology</topic><topic>human parathyroid hormone</topic><topic>Humans</topic><topic>inhalation dry powder</topic><topic>Lung - drug effects</topic><topic>Lung - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Parathyroid Hormone - administration &amp; dosage</topic><topic>Parathyroid Hormone - pharmacokinetics</topic><topic>Peptide Fragments - administration &amp; dosage</topic><topic>Peptide Fragments - pharmacokinetics</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>pulmonary deposition</topic><topic>pulmonary drug delivery</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Codrons, Valérie</creatorcontrib><creatorcontrib>Vanderbist, Francis</creatorcontrib><creatorcontrib>Ucakar, Bernard</creatorcontrib><creatorcontrib>Préat, Véronique</creatorcontrib><creatorcontrib>Vanbever, Rita</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Codrons, Valérie</au><au>Vanderbist, Francis</au><au>Ucakar, Bernard</au><au>Préat, Véronique</au><au>Vanbever, Rita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>2004-05</date><risdate>2004</risdate><volume>93</volume><issue>5</issue><spage>1241</spage><epage>1252</epage><pages>1241-1252</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004</abstract><cop>Hoboken</cop><pub>Elsevier Inc</pub><pmid>15067700</pmid><doi>10.1002/jps.20053</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 2004-05, Vol.93 (5), p.1241-1252
issn 0022-3549
1520-6017
language eng
recordid cdi_proquest_miscellaneous_71815083
source MEDLINE; Wiley Online Library Journals【Remote access available】; Alma/SFX Local Collection
subjects absorption
Absorption - drug effects
Absorption - physiology
Administration, Inhalation
Animals
Biological and medical sciences
Chemistry, Pharmaceutical
dipalmitoylphosphatidylcholine
Drug Delivery Systems - methods
General pharmacology
human parathyroid hormone
Humans
inhalation dry powder
Lung - drug effects
Lung - metabolism
Male
Medical sciences
Parathyroid Hormone - administration & dosage
Parathyroid Hormone - pharmacokinetics
Peptide Fragments - administration & dosage
Peptide Fragments - pharmacokinetics
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
pulmonary deposition
pulmonary drug delivery
Rats
Rats, Wistar
title Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T13%3A55%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20formulation%20and%20methods%20of%20pulmonary%20delivery%20on%20absorption%20of%20parathyroid%20hormone%20(1%E2%80%9334)%20from%20rat%20lungs&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Codrons,%20Val%C3%A9rie&rft.date=2004-05&rft.volume=93&rft.issue=5&rft.spage=1241&rft.epage=1252&rft.pages=1241-1252&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.20053&rft_dat=%3Cproquest_cross%3E71815083%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71815083&rft_id=info:pmid/15067700&rft_els_id=S0022354916315040&rfr_iscdi=true